These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
635 related articles for article (PubMed ID: 23139122)
21. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors. Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384 [TBL] [Abstract][Full Text] [Related]
22. Discovery of the first histone deacetylase 6/8 dual inhibitors. Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185 [TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors. Zhou M; Ning C; Liu R; He Y; Yu N Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537 [TBL] [Abstract][Full Text] [Related]
25. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600 [TBL] [Abstract][Full Text] [Related]
26. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271 [TBL] [Abstract][Full Text] [Related]
27. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768 [TBL] [Abstract][Full Text] [Related]
28. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933 [TBL] [Abstract][Full Text] [Related]
29. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors. Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003 [TBL] [Abstract][Full Text] [Related]
32. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines. Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254 [TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. Donald AD; Clark VL; Patel S; Day FA; Rowlands MG; Wibata J; Stimson L; Hardcastle A; Eccles SA; McNamara D; Needham LA; Raynaud FI; Aherne W; Moffat DF Bioorg Med Chem Lett; 2010 Nov; 20(22):6657-60. PubMed ID: 20884208 [TBL] [Abstract][Full Text] [Related]
34. 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Rajak H; Agarawal A; Parmar P; Thakur BS; Veerasamy R; Sharma PC; Kharya MD Bioorg Med Chem Lett; 2011 Oct; 21(19):5735-8. PubMed ID: 21875796 [TBL] [Abstract][Full Text] [Related]
35. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459 [TBL] [Abstract][Full Text] [Related]
36. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. Lee S; Wang SW; Yu CL; Tai HC; Yen JY; Tuan YL; Wang HH; Liu YT; Chen SS; Lee HY Bioorg Med Chem; 2021 Nov; 50():116454. PubMed ID: 34634618 [TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors. Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors. Zuo M; Zheng YW; Lu SM; Li Y; Zhang SQ Bioorg Med Chem; 2012 Jul; 20(14):4405-12. PubMed ID: 22698782 [TBL] [Abstract][Full Text] [Related]